TRINITY BIOTECH Directors Purchase Shares in the Company

DUBLIN, Ireland--(BUSINESS WIRE)--March 19, 1998--TRINITY BIOTECH PLC (Nasdaq: TRIBY-news ) announced that members of its Board of Directors had purchased 2,251,000 ordinary shares in the company through the exercise of share options.

Mr. Ronan O'Caoimh, Chairman and CEO, Mr. Brendan Farrell, President, Mr. Jonathan O'Connell, Chief Financial Officer, Mr. Jim Walsh, Chief Operating Officer and Mr. Denis Burger, Director purchased 770,000, 385,000, 400,000, 500,000 and 196,000 ordinary shares respectively.

Commenting on the purchase, Mr. Ronan O'Caoimh stated that ``this transaction reflects the confidence and belief that the Board of Directors has in the future of Trinity Biotech.'' TRINITY BIOTECH develops, manufactures and markets over 90 diagnostic products which address all three segments of the diagnostic market: point of care (POC), self testing (OTC) and the clinical laboratory. The company's products are sold in over 65 countries worldwide.

``Safe Harbor'' Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's Securities and Exchange Commission filings.

Contact:

     TRINITY BIOTECH PLC
     Jonathan O'Connell, 800/603-8076
                 or
     Lippert/Heilshorn Associates, Inc.

Back to Press Releases